| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99309 |
Subsequent nursing facility care, per day, low to moderate complexity |
84,113 |
39,515 |
$1.81M |
| 99308 |
Subsequent nursing facility care, per day, straightforward |
94,934 |
44,226 |
$1.45M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
21,175 |
18,979 |
$1.09M |
| J1745 |
Injection, infliximab, excludes biosimilar, 10 mg |
709 |
366 |
$819K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
18,903 |
16,870 |
$625K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
8,376 |
7,575 |
$431K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
2,333 |
2,149 |
$330K |
| 90960 |
End-stage renal disease related services monthly, for patients 20 years and older, with 4 or more face-to-face visits |
4,776 |
4,414 |
$286K |
| 99306 |
Prolong nursin fac eval 15m |
2,575 |
2,351 |
$195K |
| 88313 |
|
1,326 |
1,221 |
$97K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
1,036 |
947 |
$82K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
900 |
776 |
$82K |
| 88312 |
|
1,205 |
1,121 |
$63K |
| J3380 |
Injection, vedolizumab, intravenous, 1 mg |
16 |
13 |
$56K |
| 99215 |
Prolong outpt/office vis |
557 |
488 |
$31K |
| 99307 |
|
3,556 |
1,923 |
$26K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
488 |
441 |
$21K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
3,397 |
1,039 |
$20K |
| 99305 |
|
364 |
331 |
$19K |
| 11102 |
|
535 |
407 |
$18K |
| 99349 |
|
1,003 |
816 |
$15K |
| 99497 |
|
1,187 |
1,062 |
$10K |
| 96415 |
|
549 |
505 |
$9K |
| 99310 |
Prolong nursin fac eval 15m |
594 |
464 |
$9K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
152 |
142 |
$7K |
| 99318 |
|
189 |
184 |
$5K |
| 99316 |
|
80 |
76 |
$4K |
| 99205 |
Prolong outpt/office vis |
38 |
38 |
$3K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
28 |
26 |
$3K |
| 90674 |
|
150 |
136 |
$3K |
| 17110 |
|
60 |
53 |
$3K |
| 46600 |
|
117 |
100 |
$3K |
| 99304 |
|
112 |
101 |
$2K |
| 99223 |
Prolong inpt eval add15 m |
90 |
66 |
$2K |
| 99406 |
|
307 |
261 |
$2K |
| 99233 |
Prolong inpt eval add15 m |
191 |
61 |
$2K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
12 |
12 |
$2K |
| 90966 |
|
27 |
26 |
$1K |
| 99335 |
|
72 |
33 |
$923.00 |
| 99348 |
|
190 |
145 |
$871.64 |
| 96127 |
|
62 |
57 |
$845.01 |
| 99336 |
|
30 |
13 |
$791.56 |
| 99498 |
|
210 |
189 |
$791.41 |
| 93000 |
|
76 |
61 |
$710.26 |
| G0179 |
Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care |
72 |
64 |
$590.13 |
| J7050 |
Infusion, normal saline solution, 250 cc |
1,098 |
993 |
$557.38 |
| 90715 |
|
15 |
12 |
$361.60 |
| 99231 |
Subsequent hospital care, per day, straightforward or low complexity |
111 |
50 |
$355.05 |
| 91065 |
|
13 |
12 |
$286.44 |
| 99315 |
|
12 |
12 |
$158.75 |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
13 |
12 |
$120.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
163 |
150 |
$56.30 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
15 |
13 |
$12.02 |
| 3079F |
|
79 |
77 |
$0.00 |
| 3074F |
|
158 |
150 |
$0.00 |
| 90694 |
|
17 |
17 |
$0.00 |
| 3075F |
|
54 |
51 |
$0.00 |
| 3078F |
|
309 |
299 |
$0.00 |